Allogene Q2 net loss $66.4M ($0.35/sh); initiated pivotal ALPHA3 trial for cema-cel

Allogene Therapeutics, Inc.

2024-Q2 EPS reported -$0.73 revenue$22,000

Net loss of $66.4M ($0.35 per share) includes $13.6M stock-based comp and $5.0M impairment.
Cash, equivalents and investments $444.6M as of June 30, 2024; runway into 2H 2026.
Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL initiated; enrollment completion expected 1H 2026, BLA submission 2027.
ALLO-329 (CD19/CD70 dual CAR) IND on track for Q1 2025 in autoimmune disease; proof-of-concept by YE 2025.
ALLO-316 Phase 1 TRAVERSE data update with ~20 RCC patients planned for YE 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.